TTR siRNA Lipid Nanoparticle Therapy for hATTR Progression Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for transthyretin (TTR) amyloidosis, such as liver transplantation and stabilizing TTR tetramers with tafamidis, fail to halt disease progression in a significant proportion of patients, highlighting the need for new, disease-modifying therapies.

Innovation Solution

Administration of patisiran, a small interfering ribonucleic acid (siRNA) formulated in a hepatotropic lipid nanoparticle, targets and degrades TTR mRNA, reducing serum TTR protein levels, thereby stabilizing or improving clinical endpoints in hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis).

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If liver transplantation is performed to reduce mutant TTR levels, then survival is improved in early-stage FAP, but deposition of wild-type TTR continues and disease progression is not halted in significant proportion of patients

Engineering Contradiction:

Improvedisease progression controlVSAvoidtreatment effectiveness across patient population

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent extracts and removes the harmful TTR mRNA from the system using siRNA molecules that specifically bind to and degrade TTR mRNA, thereby preventing TTR protein production and amyloid deposition without requiring liver transplantation

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces lipoprotein particles as intermediary carriers that deliver siRNA molecules to hepatocytes, enabling targeted gene silencing in the liver while avoiding the need for organ transplantation and addressing the limitations of current treatments

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If tafamidis is used to stabilize TTR tetramers, then disease progression is slowed, but symptoms continue to worsen in a large proportion of patients, indicating insufficient disease modification

Engineering Contradiction:

Improvedisease progression controlVSAvoidsymptom improvement rate

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

Instead of stabilizing the TTR tetramer to prevent misfolding (the conventional approach with tafamidis), the patent inverts the strategy by using siRNA to degrade TTR mRNA before protein synthesis occurs,从根本上 preventing the production of both mutant and wild-type TTR proteins that contribute to amyloid deposition

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The patent performs preliminary action by degrading TTR mRNA in the liver before TTR protein can be synthesized and deposited in tissues, thereby preventing disease progression and allowing symptom improvement without waiting for tetramer destabilization to occur

Inventive Principle:

Principle #10Preliminary action

3Reliability

If siRNA is administered to reduce TTR protein levels, then serum TTR concentration is reduced and clinical endpoints are stabilized, but delivery to target hepatocytes must be achieved efficiently

Engineering Contradiction:

ImproveTTR protein reduction efficacyVSAvoiddelivery system complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses lipoprotein particles as intermediary carriers that naturally target hepatocytes through receptor-mediated endocytosis, simplifying the delivery system by leveraging the body's existing lipid metabolism pathways rather than requiring complex engineered delivery mechanisms

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The lipoprotein particles serve multiple functions: they protect siRNA from degradation, facilitate hepatocyte uptake through natural receptor interactions, and enable targeted delivery to the liver, thereby simplifying the overall delivery system through a multi-functional carrier

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Patisiran effectively reduces serum TTR protein concentration, leading to stabilization or improvement of neuropathy and cardiomyopathy symptoms, as measured by Neuropathy Impairment Scores and echocardiogram parameters.

Implementation Method 1

a small interfering ribonucleic acid (siRNA) formulated in a hepatotropic lipid nanoparticle

Methodology Applied

Scientific EffectHepatotropic targeting:

Implementation Method 2

formulated in a hepatotropic lipid nanoparticle

Methodology Applied

Scientific EffectLipid nanoparticle delivery:

Implementation Method 3

targets and degrades TTR mRNA, reducing serum TTR protein levels

Methodology Applied

Scientific EffectRNA interference:

Data Source

PatentUS20260053839A1Compositions and methods for treating transthyretin (TTR) mediated amyloidosis

Publication Date: 2026.02.26 ALNYLAM PHARMACEUTICALS INC

AI summary

Disclosed herein are methods for treating hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in a human patient in need thereof by administering an effective amount of a transthyretin (TTR)-inhibiting composition.